Alkermes (ALKS +5%) discusses three new drug candidates at its R&D day: An MS prodrug...

|About: Alkermes plc (ALKS)|By:, SA News Editor

Alkermes (ALKS +5%) discusses three new drug candidates at its R&D day: An MS prodrug program, a treatment for pain, and a cancer immunotherapy candidate. The company also announces the initiation of a Phase II study for the schizophrenia treatment ALKS 3831.